SARA VERDURA MARTINEZ

Projectes

Metabolisme i Càncer

Ayuda de personal Miquel Servet

Codi oficial: CP20/00003 Data inici: 01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III

Metabolisme i Càncer

Modificaciones postraduccionales de PD-L1 en la inmunoterapia del cáncer: Desarrollo de nuevas estrategias terapéuticas y fármaco-diagnósticas

Codi oficial: PI22/00297 Data inici: 01/01/2023 Data fi: 31/12/2025 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ, ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III

Metabolisme i Càncer

Un nuevo enfoque de la actividad ácido graso sintasa como sistema de procesamiento de información en la oncología de precisión funcional

Codi oficial: PID2022-141955OB-I00 Data inici: 17/10/2023 Data fi: 31/08/2026 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA E INNOVACION

Publicacions

Metabolisme i Càncer

Menendez JA, Cuyàs E, Encinar JA, Steen TV, Verdura S, Llop-Hernández À, López J, Serrano-Hervás E, Osuna S, Martin-Castillo B, Lupu R

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

MOLECULAR ONCOLOGY, 2024, 18, 479-516 dx.doi.org/10.1002/1878-0261.13582

Metabolisme i Càncer , Oncologia de Precisió de Girona

Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493

Metabolisme i Càncer , Oncologia de Precisió de Girona

Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Cell Death Discovery, 2024, 10, 417-417 dx.doi.org/10.1038/s41420-024-02184-z

Epidemiologia descriptiva, genètica i prevenció del càncer , Oncologia de Precisió de Girona , Metabolisme i Càncer

Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

LUNG CANCER, 2024, 197, 107995-107995 dx.doi.org/10.1016/j.lungcan.2024.107995

Oncologia de Precisió de Girona , Metabolisme i Càncer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Metabolisme i Càncer

Cuyàs, E, Verdura, S, Martin-Castillo, B, Menendez, JA

Circulating levels of MOTS-c in patients with breast cancer treated with metformin

Aging-Us, 2023, 15, 892-897

Epidemiologia descriptiva, genètica i prevenció del càncer , Oncologia de Precisió de Girona , Imatge Mèdica , Metabolisme i Càncer , Hematologia

Bosch-Barrera, J, Teixidor, E, Sanvisens, A, Puigdemont, M, Trallero, J, Vila, AV, Osca, G, Roberte, MV, Priego, N, Sais, E, Martínez, AH, Ortega, JS, Cuyàs, E, Verdura, S, Puig, J, Pineda, V, Martí-Navas, M, Calvo, A, Menendez, JA, Marcos-Gragera, R, Valiente, M

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

JOURNAL OF THORACIC ONCOLOGY, 2023, 18, 426-427

Metabolisme i Càncer , Epidemiologia descriptiva, genètica i prevenció del càncer , Oncologia de Precisió de Girona

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Metabolisme i Càncer

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882

Metabolisme i Càncer

Yang, L, Vander Steen, T, Espinoza, I, Cuyas, E, Verdura, S, Menendez, JA, Lupu, R

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 2173-2188

12 3 4 5

Directori

Projectes

Publicacions

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Circulating levels of MOTS-c in patients with breast cancer treated with metformin

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

Formulari de contacte

Coneix l’IDIBGI!